Introduction
============

Despite efforts in the search for antibiotics in general, new discoveries do not translate into new classes of rapidly applicable pharmaceuticals. Over the past 30 years, only two novel classes of antibiotics have been launched on the market: the oxazolidinone linezolid and the cyclic lipopeptide daptomycin ([@b27-bmj-44-4-1007]). This small number of novel compounds demonstrates the inadequacy of traditional approaches, prompting the search for new strategies, among which metagenomics, bioinformatics and molecular engineering emerge as the most promising alternatives to balance this constant battle for human and environmental health.

Polyketides are natural metabolites that comprise the basic chemical structure of various anticancer, antifungal, and anticholesteremic agents; antibiotics; parasiticides and immunomodulators. As a testimony to its importance, the annual sales of pharmaceuticals derived from polyketides routinely reach 20 billion dollars ([@b104-bmj-44-4-1007]).

Since the discovery of the antibiotic properties of polyketides (*i.e.*, streptomycin in 1950), the search for new compounds has led pharmaceutical companies to isolate tens of millions of antibiotic producing strains though cultivable soil microorganisms remain the main source of antibiotics and other active compounds. However, traditional methods for searching new drugs, which involve the cultivation of microorganisms isolated from soil, are not so promising currently. Some estimates of the high rate of rediscovery of known antibiotics produced by this technique are quite pessimistic: they were reaching 99.9% ([@b107-bmj-44-4-1007]; [@b13-bmj-44-4-1007]). On the other hand, some studies draw an interesting parallel between the discovery of certain new compounds not only in new species, but also in known species, reflecting both the under-exploitation of a minority of compounds produced by certain microorganisms and the constant acquisition of new polyketide synthase (PKS) pathways by unrelated species through horizontal gene transfer ([@b96-bmj-44-4-1007]).

As an alternative to these barriers, an emerging method for obtaining biomolecules with new or improved pharmacological properties is the direct study of genetic material from complex environmental samples called Metagenomics. By using this approach, it is possible to recover and express genes from uncultivable bacteria (which can be correspond to 99% of the total) because metagenomics is based on the genomic analysis of microorganism communities without the need to culture them in the laboratory. Therefore, metagenomics consists of extracting DNA directly from the environment and constructing a genomic library from this mixture ([@b56-bmj-44-4-1007]; [@b14-bmj-44-4-1007]). Then, these materials can be mining for genes of biotechnological interest, both for genetic homology as functional screening. This technique has been the source of many new bioactive compounds; among them we can cite psymberin, norcardamine, violacein and turbomycin A ([@b5-bmj-44-4-1007]; [@b51-bmj-44-4-1007]; [@b46-bmj-44-4-1007]).

How an important tool for the discovery of new genetic pathways from metagenomics, bioinformatics analyses aid in the screening of promising sequences through the identification of possible genes, and functional inferences are based on homology and on simulations of the structural conformation of the expressed protein ([@b91-bmj-44-4-1007]; [@b28-bmj-44-4-1007]). Using metagenomics, it is possible to recover and study new PKS gene sequences, which can be used in cloning, combinatorial biosynthesis, and heterologous expression experiments to obtain new molecules.

This study presents an analysis of the current view in the search for new antibiotics with greater focus on the advances in the polyketides field and a discussion of the delicate dual role hero/villain of new bioactive compounds in the emergence of multidrug-resistant pathogens. For didactic purposes and considering that this fascinating group of biomolecules arouses the attention of researchers worldwide, some aspects of PKS biochemical pathway organization and a discussion of the main obstacles for developing this research field are presented. Lastly, we present recent results obtained in our laboratory related to this exploration.

Secondary Metabolite-Producing Microorganisms
=============================================

Secondary metabolites are natural compounds produced by certain groups of bacteria, fungi and plants. These compounds are usually active against microorganisms at low concentrations due to their ability to inhibit essential primary metabolic processes. These metabolites are called "secondary" because they are not essential for cell survival, but their production often confers a competitive advantage to the microorganism ([@b63-bmj-44-4-1007]).

Many secondary metabolites of biotechnological interest are produced by a group of filamentous gram-positive bacteria of the *Actinomycetales* order. The genus *Streptomyces,* which is in the *Streptomycetaceae* family, is the most well known in this order ([@b59-bmj-44-4-1007]), and it mainly includes bacteria found in the soil and aquatic environments. These microorganisms are able to utilize different carbon sources and secrete a variety of hydrolytic enzymes that degrade insoluble organic materials such as cellulose and chitin ([@b65-bmj-44-4-1007]; [@b43-bmj-44-4-1007]).

These microorganisms exhibit colony morphological differentiation that is coordinated with physiological differentiation and secondary metabolite synthesis. The life cycle of these microorganisms begins with spore fixation to their substrate and germination, resulting in filaments that are often "multinucleated" (*i.e.*, a mixture of nucleic acids from more than one microorganism, and they lack a nuclear membrane because they occur in bacteria), which are called hyphae. In response to specific signals, which usually include nutritional deficiency, there is the formation of another type of mycelium called aerial mycelium, which emerges from the surface of the colony. Concomitantly, the presence of secondary metabolites is detected in the substrate. The aerial mycelium is formed of dividing septa with double cell walls, and each septum has a genome that will result in a spore for the dispersion and colonization of new habitats ([@b12-bmj-44-4-1007]).

This genus has the ability to synthesize secondary metabolites with highly diverse chemical structures including a wide variety of antibiotics, and many of these compounds have important applications in medicine and agriculture ([@b101-bmj-44-4-1007]; [@b76-bmj-44-4-1007]). Among the filamentous actnomycetes, 75% of all metabolites are produced by the genus *Streptomyces*, the major source of the antibiotics sold worldwide ([@b72-bmj-44-4-1007]; [@b93-bmj-44-4-1007]). *Streptomyces* have a large linear chromosome of approximately 8 Mb, with high C+G content (*i.e.*, 69 to 74%) ([@b31-bmj-44-4-1007]; [@b36-bmj-44-4-1007]; [@b52-bmj-44-4-1007]). *Streptomyces* have both linear and circular plasmids with sizes ranging from 2 kb to 1 Mb, and they may be involved in conjugation events ([@b7-bmj-44-4-1007]; [@b52-bmj-44-4-1007]), biosynthesis ([@b38-bmj-44-4-1007]), and antibiotic resistance ([@b53-bmj-44-4-1007]; [@b47-bmj-44-4-1007]).

Many factors can potentially determine the onset of antibiotic production in *Streptomyces.* The existence of a complex regulatory network enables the organisms to respond to a variety of physiological and environmental signals ([@b82-bmj-44-4-1007]).

Morphological differentiation and the onset of antibiotic production are related to the type and availability of carbon and nitrogen sources ([@b63-bmj-44-4-1007]), and to low molecular weight diffusible substances, which act as autoregulators and determine the initiation of antibiotic production and morphological differentiation. One example of an autoregulator is the A-factor, a γ-butyrolactone whose presence at nanomolar concentrations promotes the formation of aerial mycelium and the production of streptomycin in *S. griseus* ([@b42-bmj-44-4-1007]). In *S. coelicolor* A3 (strain 2), a model-organism actinobacteria for molecular genetic studies whose complete genome has been sequenced, the genes that express γ-butyrolactones are located outside the gene cluster ([@b6-bmj-44-4-1007]) and are pleiotropic regulators of other specific biosynthetic pathway regulators ([@b41-bmj-44-4-1007]).

Antibiotics Produced by Microorganisms: Polyketides
===================================================

Polyketides are natural products containing multiple β-hydroxyketone or β-hydroxyaldehyde (-H~2~C(=O)CH~2~CH(OH)CH~2~C(=O)-) functional groups. The PKSs are diverse enzymatic complexes that catalyze polyketide carbon skeleton assembly from coenzyme-A fatty esters that are derived from short-chain fatty acids such as acetate, propionate and butyrate. The fatty acid synthases (FASs) are homologous to PKSs and synthesize lipids involved in a wide variety of essential cellular functions; however, PKSs have a much more complex biosynthetic routine and are only present in restricted taxonomic groups ([@b40-bmj-44-4-1007]). Although both polyketides and fatty acids are derived from acetyl-CoA or other acyl-CoAs, in polyketides, more than one monomer type may be used to construct different sizes of aromatic or reduced chains ([Figure 1](#f1-bmj-44-4-1007){ref-type="fig"}). These chains can be as small as 6 to 8 carbons long (*e.g.*, 6-methyl salicylic acid; 6-MSA), or as large as 164 carbon atoms (*e.g.*, maitotoxin). In fatty acids, only groups with two carbons are assimilated from malonyl-CoA to form saturated molecules with chain sizes ranging from 16 to 20 carbons long ([@b45-bmj-44-4-1007]; [@b104-bmj-44-4-1007]).

Three classes of bacterial PKSs have been identified to date: type I, type II and type III (Shen *et al.*, 1994). The type I PKSs (*i.e.*, modular/iterative PKSs) are large enzymes, consisting of multi-domains that contain a series of active sites for the various stages of polyketide synthesis. Examples of natural products derived from these multicatalytic enzymes include the macrolides (erythromycin) and polyenes (nystatin). The type II PKSs (*i.e.*, aromatic PKSs) are composed of separate mono and bi-functional enzymes that interact during synthesis to form a polyketide structure. This structure is then enzymatically converted to the cyclic form to produce polycyclic aromatic compounds such as tetracycline or doxorubicin ([@b45-bmj-44-4-1007]).

The type III PKSs, which are also called chalcone synthases, are relatively small proteins that are mainly involved in the production of important plant compounds such as flavonoids and stilbenes (phenolic), and they are also found in bacteria and fungi. Unlike other PKSs, PKS III polyketide intermediates are not linked enzymatically but through free coenzyme-A thioesters ([@b8-bmj-44-4-1007]).

Among the three PKSs, the most well-studied pathways for combinatorial biosynthesis are the type I PKSs, which allowed for the development of databases specific for this family and an efficient system for the comparison of enzymatic domains capable of predicting the majority of substrates through software based on homology ([@b105-bmj-44-4-1007]; [@b94-bmj-44-4-1007]). This level of knowledge has not been achieved yet for type II PKSs, and due to their ecological and biotechnological importance, it is essential that similar prediction methods be developed to help guide proteomics and molecular engineering research.

One of the foremost scientists involved in studying PKSs was Professor Charles Richard Hutchinson who dedicated a part of his life to conducting detailed studies on these important classes of enzymes ([@b97-bmj-44-4-1007]; [@b70-bmj-44-4-1007]). The death of Dr. Hutchinson on January 5, 2010 was undoubtedly a great loss to academic research in this field. The legacy of Dr. Hutchinson ([@b70-bmj-44-4-1007]) and the results of 40 years dedicated to PKS studies involving the search for new drugs, particularly against cancer (ironically, the disease that killed him at age 66) include the study of bacterial and fungal polyketides. Among the type I PKSs, Hutchinson and colleagues studied the erythromycin, geldanamycin, herbimycin, lasalocid, megalomycin, midecamycin, rapamycin and rifamycin synthesis pathways. In the type II PKS family, these researchers studied the elloramycin, doxorubicin, daunorubicin, fredericamycin, jadomycin and tetracenomycin synthesis pathways.

As shown in [Figure 2](#f2-bmj-44-4-1007){ref-type="fig"}, the modular PKS I ([Figure 2A](#f2-bmj-44-4-1007){ref-type="fig"}) has noniterative action. The reaction begins with an activation module (*i.e.*, the loading module), that binds through a thioester bond of the initial precursor with the acyl carrier protein (ACP) by the action of the first acyltransferase (AT) site. Next, there is the transfer of the activated substrate to the ACP of the next module in a reaction known as the "*ping-pong*" mechanism. The enzymes of this module move the reaction process forward by adding a new monomer to the ketone chain and modify the group by oxidation-reduction reactions and transferase activity. This newly formed molecule will subsequently be the substrate for the next module. The final step of the reaction is the action of thioesterase (TE), which releases the ACP-bound polyketide molecules from the termination module. It is important to note that this is not the only PKS I group reaction type, there are *cis* AT, *trans* AT and iterative PKS I (one or two modules rotate the reaction steps between each other, and the same gene gives rise to multiple copies of the polypeptide, which interacts in the reactions) ([@b104-bmj-44-4-1007]).

Both PKS II ([Figure 2B](#f2-bmj-44-4-1007){ref-type="fig"}) and PKS III ([Figure 2C](#f2-bmj-44-4-1007){ref-type="fig"}) are iterative. However, PKS II action in the initial ketone chain synthesis involves the interaction of three enzymatic subunits: KSα, KSβ and ACP. First, the initial precursor (mostly acetyl-CoA) forms a thioester bond with the ACP. The reaction is catalyzed by KSα, but it can also spontaneously occur in vitro. Next, the first chain is constructed by a Claisen condensation reaction (*i.e.*, a reaction between two esters or an ester and a ketone group in the presence of a strong base or a catalytic site, producing a β-keto ester or β-diketone, respectively) of a new substrate (*i.e.*, malonyl-CoA and methyl-malonyl-CoA), which is catalyzed by KSα and KSβ subunits over the beginning of the chain still bound to the ACP ([@b104-bmj-44-4-1007]).

The Claisen condensation reaction is repeated numerous times with the elongating chain always anchored to the ACP and with the constant action of the same enzymes hence the name iterative. During ACP-anchored synthesis, various additional enzymatic units (*e.g.*, cyclases and aromatases) act on this chain producing aromatic and cyclic groups, or they reduce the ketone groups. After the release of the polyketide from the ACP, numerous other enzymes, such as oxidases, transferases and hydrolases, act on the chain to make post-synthetic modifications ([@b104-bmj-44-4-1007]).

In turn, PKS III is surprisingly composed of only one KS domain, and the initial precursor is derived by the direct binding of free acetyl-CoA to the KS catalytic site, which performs the entire Claisen condensation reaction alone. The catalytic site redox potential and the instability of some chemical groups in the elongation chain will induce spontaneous chain cyclization ([@b8-bmj-44-4-1007]; [@b104-bmj-44-4-1007]).

All biosynthetic genes necessary for the synthesis of a given antibiotic from primary metabolites occur in gene clusters occupying between 15 and 120 kb. These clusters contain genes that confer antibiotic auto-resistance and regulatory genes that coordinate the expression of other genes in the cluster in addition to structural genes encoding all enzymes of the secondary metabolic pathway ([@b25-bmj-44-4-1007]). This was first demonstrated through the cloning of the entire actinorhodin biosynthetic gene cluster, which was found on a 35 kb chromosomal DNA fragment of the producer *Streptomyces coelicolor* A3 (strain 2) and its expression in the non-producer and actinorhodin-sensitive strain *S. parvulus*, which produced actinorhodin and became resistant ([@b62-bmj-44-4-1007]). Gene knockout experiments, complementation of blocked mutants and heterologous expression allowed for the biosynthetic gene clusters to be studied in detail, leading to the isolation and characterization of entire biosynthetic pathways ([@b44-bmj-44-4-1007]).

Multidrug- and Pandrug-Resistant Bacteria
=========================================

It has been long known that microorganisms have several mechanisms of drug resistance, which arise from natural selection of the "gene pool" of constantly evolving microbial populations either by gene mutations (vertical evolution) or by the acquisition of genes from other non-related species through mobile genetic elements such as plasmids, phages and transposons (*i.e.*, horizontal gene transfer). [Figure 3A](#f3-bmj-44-4-1007){ref-type="fig"} shows some of the major mechanisms of bacterial resistance to known antibiotics. Historically, the inappropriate use of pharmacological compounds in the clinical setting has placed artificial selection on the microbiota, accelerating the spread of resistance among pathogen and commensal microorganisms. As observed in [Figure 3B](#f3-bmj-44-4-1007){ref-type="fig"}, the emergence of resistant pathogens in a hospital environment typically occurs shortly after the introduction of a new compound ([@b84-bmj-44-4-1007]).

Despite this situation, the emergence of genes related to antibiotic resistance preceded the clinical use of antibiotics by humans and should not be understood as the result of this selection but as its raw material. Microbial antibiotic resistance and pathogenicity are not modern phenomena. Studies using metagenomic DNA samples extracted from Beringian permafrost sediments that were protected from contamination by layers of volcanic tephra (C^14^ dated at 30,000 years old, belonging to the Pleistocene) revealed the presence of several gene clusters encoding resistance to β-lactam, tetracyclines, glycopeptide antibiotics and the presence of sequence variants similar to the modern vancomycin resistance element VanA ([@b17-bmj-44-4-1007]). This demonstrates the natural course of the emergence of these genes through evolution, suggesting that their role in the antagonistic relations within the microbial community precedes the effects of human action.

If the constant adaptation of microorganisms to drugs in the circulation has required a constant search for new formulations, then the emergence of multidrug resistant bacteria classes has made the discovery of novel chemical molecules a priority. Some promising approaches have emerged, such as prospecting in unexplored bacterial niches, database searching for synthetic molecules ([@b27-bmj-44-4-1007]) and the use of metagenomics.

The first class corresponds to the methicillin-resistant *Staphylococcus aureus* (MRSA), and this group is identified as the cause of 19,000 annual deaths in the United States and an annual increase in health costs on the order of 3 to 4 billion dollars. As an aggravating factor, the prevalence of MRSA increases the likelihood of vancomycin resistant *S. aureus* (VRSA), further challenging disease treatment in hospitals ([@b27-bmj-44-4-1007]).

The second class includes gram-positive multidrug-resistant (MDR; with resistance to certain drugs) and pandrug-resistant (PDR; with resistance to all drugs) bacteria, which are less prevalent than MRSA, which are albeit related to incurable clinical pictures. The strains *Acinetobacter baumannii*, *Escherichia coli*, *Klebsiella pneunominae*, and *Pseudomonas aeruginosa* are MDR/PDR to penicillin, cephalosporin, carbapenem, monobactam, quinolone, aminoglycoside, tetracycline and polymyxin ([@b27-bmj-44-4-1007]).

The third class is comprised of *Mycobacterium tuberculosis* strains that are MDR and extensively drug resistant (XDR), and they are a growing problem in developing countries, requiring treatment for two years with antibiotics that cause severe side effects ([@b27-bmj-44-4-1007]).

This situation brings up the discussion of the misuse of drugs, which for years has accelerated this resistance process that is caused by generations of microbes that are resurgent from treatments that are insufficient in duration and dose. This concern has also led to the creation of stricter rules for the purchase of antibiotics such as the recent decision by the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária - ANVISA) for the mandatory submission of a prescription to purchase antibiotics, thereby curbing self-medication.

Pharmaceutical Market and the Discovery Pipeline
================================================

Over the past 30 years, only two novel classes of antibiotics have been launched on the market: the oxazolidinone linezolid and the cyclic lipopeptide daptomycin. As an aggravating factor, telavancin (a glycopeptide), retapamulin (a pleuromutilin), and tigecycline (last generation tetracycline) were the only antibiotic active ingredients approved as entirely new molecules by the U.S. Food and Drug Administration (FDA), and they were launched on the market between 2005 and 2010. In addition, there are few antibiotics in circulation that are still considered to be safe in terms of retaining their active capacity against MDR micropathogens ([@b37-bmj-44-4-1007]).

This decline is also marked by an uneven distribution of molecules within the different classes of antibiotics with a predominance of polyketide compounds, which included one third of all drugs brought to market from 2005 to 2007 ([@b104-bmj-44-4-1007]). [Figure 4A](#f4-bmj-44-4-1007){ref-type="fig"} illustrates the revenues earned in billions of dollars for each of the main active ingredients of drugs marketed worldwide in 2009, particularly for the cephalosporin class of polyketides, which accounted for 11.9 billion dollars. However, the crisis scenario is marked by the slow process between prospection and the arrival of the molecule on the consumer market. [Figure 4B](#f4-bmj-44-4-1007){ref-type="fig"} illustrates the distribution profile of molecules in the pre-implementation phase in 2010, and it shows that beyond the actual discovery process of new bioactive compounds, the major bottleneck of the process is the pre-clinical period ([@b37-bmj-44-4-1007]).

Another factor that greatly contributes to the retention time of each drug at every stage is the nature of its application and urgency in the demand for certain clinical groups as shown in [Figure 5](#f5-bmj-44-4-1007){ref-type="fig"} ([@b48-bmj-44-4-1007]).

As observed in [Figure 5](#f5-bmj-44-4-1007){ref-type="fig"}, HIV drugs have been the fastest implemented, and this is, in part, due to the speed at which current drugs become ineffective in the face of new prevalent serotypes. These classes of drugs and antineoplastic agents have the shortest regulation time (approval phase), which reflects a clear reduction in the bureaucratic process involving the release of these drugs, ensuring a more dynamic exchange between the academic/technical/scientific sector and the community.

Another aspect to be considered is the process of generating new drugs, which identifies the institutions that contribute the most to their generation. [Figure 6](#f6-bmj-44-4-1007){ref-type="fig"}, for example, illustrates the origin of the 252 new drugs approved by the FDA from 1998 to 2007.

As observed in the graph in [Figure 6](#f6-bmj-44-4-1007){ref-type="fig"}, the United States is responsible for most of the drugs produced, and universities represented an important focus for the generation of new products for the biotechnology private sector, surpassing the performance of large pharmaceutical companies ([@b55-bmj-44-4-1007]). These data reinforce the essential role of universities in creating new drugs, clearly demonstrating how the public and private sector could invest to boost new drugs production.

In Brazil, the regulation of new drug implementation priorities is the responsibility of the National Drug Policy ("Política Nacional de Medicamentos" - PNM) and the National Health Surveillance Agency (ANVISA). The PNM was established in 1998 and is responsible for regulating the list of drugs considered essential and the safety standards for medicine, human resources and technical/scientific development. Though the list of essential drugs already existed, it had not been updated for approximately 16 years. The PNM was responsible for reformulating the list in 1999, and it was subsequently updated in 2002 and 2006. The ANVISA, was created in 1999 with the priority of addressing issues of health surveillance ([@b100-bmj-44-4-1007]).

An important health step in Brazil, where 70% of the population has access to public health, was the passing of the generic drug policy and the breaking of drug patents in 1999. Four years after the passing of this policy, generic drugs already represented 12% of the total drug sales in the country. Of the remaining drug sales, 68% corresponded to similar drugs (*i.e.*, non-patented), and 20% corresponded to drugs protected by patents ([@b100-bmj-44-4-1007]). This practice allowed a more democratic access to drugs considered essential to health.

The importance of generic and similar drugs is undeniable because they represent the most attractive options in an industry where it is common practice for drugs with the same formulation to differ only in brands and prices. [@b102-bmj-44-4-1007] analyzed new drugs brought to market in Brazil between 1998 and 2001 ([Figure 7](#f7-bmj-44-4-1007){ref-type="fig"}).

From the 285 "new" drugs approved by the ANVISA, 84 were considered non-innovative (red) because they had the same formulations as drugs previously released. Of the remaining drugs, 47 were not targeted in the author's study (yellow), and 154 drugs (in blue) contained a new chemical molecule in their formulation ([@b102-bmj-44-4-1007]).

Historically, pharmaceutical corporations in Brazil, both national and transnational, have focused on the modification of pharmaceuticals, relegating the discovery of new formulations to the background with scarce resources. Fortunately, this situation is beginning to change with the increased investment and involvement of companies in all of the developmental and production stages of new drugs, which seems to have a close relationship with changes in the regulatory policies for this sector, a production capacity expansion and a favorable economic environment coupled with the consolidation of university research. In fact, an increase in the creation of study groups and a greater interaction between these and the pharmaceutical companies have expanded the research capacity for new products, culminating in the first drug developed entirely in Brazil in 2004: the anti-inflammatory alpha-humulene ([@b100-bmj-44-4-1007]) that is derived from the plant species *Cordia verbenacea,* which is known by its popular name of "erva-baleeira." Thus, it is clear that the worldwide market for drugs is still dominated by large pharmaceutical and biotechnology companies with active academic participation in the development of new formulations, and that the United States is the largest producer of pharmaceuticals.

Other developed countries share the responsibility for the remainder of the new formulations. Although still in its early stages, Brazil has made progress in the technical/scientific development of new drugs; however, there is still much to be done to ensure democratic access to medications, and investment in academic research seems to be a promising path that has already been well established in developed countries, showing the successful implementation of partnership strategies between universities and public/private initiatives.

Metagenomics as a Tool for Discovery of Novel Polyketides
=========================================================

The recent widespread dissemination of pathogenic bacteria resistant to antibiotics and the increasing need for bioactive molecules with new or improved pharmacological properties promoted an increased interest in the discovery of new antibiotics ([@b19-bmj-44-4-1007]).

Traditionally, the discovery of novel bioactive compounds with biotechnological importance is performed by analyzing natural sources, such as soil microorganisms, for the presence of desired activities. Since the discovery of streptomycin in the 50s, which is produced by a soil-isolated actinobacteria, microbiologists and pharmacists around the world have invested great efforts in the culture of various microorganisms in the search for new strains able to synthesize antibiotics. The search for new antibiotics has led pharmaceutical companies to isolate tens of millions of producing strains. To date, cultivable soil microorganisms still represent the main source of antibiotics and other active compounds.

Currently, traditional methods for the searching for new drugs involving the cultivation of soil microorganisms are not as promising, and this is mainly due to the high rediscovery rate of known antibiotics, which reaches 99.9% ([@b107-bmj-44-4-1007]; [@b13-bmj-44-4-1007]). However, progress in molecular microbial ecology has demonstrated that the genetic diversity of microorganisms in nature is much greater than that reflected in the lineage collections and databases. It is estimated that only a small portion of these, approximately 1%, is cultivable by standard culture media techniques ([@b1-bmj-44-4-1007]; [@b14-bmj-44-4-1007]).

The vast majority of microorganisms have needs that are too complex to be reproduced in artificial environments including microorganisms that have synergisms/syntrophisms with other organisms, and those requiring amino acid supplementation, unusual carbohydrates, growth factors and a whole set of physical-chemical factors produced by the metabolism of other microorganisms such as optimal pH and moisture, harmful metabolic waste reduction, and the creation of anaerobic or aerobic environment among many other interactions.

Metagenomics is a method based on the genetic and functional analysis of the microbiota without culturing, and it directly acts on the nucleic acid pool in the environment. In one of its applications, the methodology makes use of the PCR amplification of conserved gene regions followed by amplicon cloning and sequencing, creating so-called gene diversity libraries ([@b14-bmj-44-4-1007]; [@b34-bmj-44-4-1007]).

Some regions that are highly conserved across all genomes, such as genes corresponding to ribosomal RNA synthesis (*i.e.*, rDNA and rRNA), particularly the 16S rDNA (prokaryotes) and 18S rDNA (eukaryotes), allow the classification of organisms thanks to the intercalation of variable and non-variable sequences.

Studies employing the amplification of 16S and 18S rDNA from DNA samples extracted directly from the environment are dramatically changing the traditionally accepted phylogenetic definitions of the main microbial groups ([@b10-bmj-44-4-1007]).

Other gene regions also enable tracking this diversity and are often used to determine the abundance of a specific group of enzymes or regulators among the other proteins present in a given community. These regions are important to infer the ecological role played by proteins in maintaining the ecosystem studied and identifying environments rich in biotechnologically interesting enzymes ([@b67-bmj-44-4-1007]).

Another metagenomics methodological approach is the extraction of high-molecular-weight and pure DNA and the cloning of this material in vectors that can carry large inserts such as BACs and YACs (*i.e.*, bacterial artificial chromosomes and yeast artificial chromosomes, respectively) and cosmids and fosmids, thus creating metagenomic libraries that are searchable for genes of ecological and/or biotechnological interest, enabling the discovery of previously unknown biosynthetic pathways. One major barrier to the implementation of this technique is obtaining high quality DNA due to contamination with co-extracted environmental materials such as fulvic and humic acids ([@b79-bmj-44-4-1007]). This need became significant because of the fact by which pathways antibiotics are produced, once they can be extremely complex, reaching up to 100 kb of genomic extension and with more than 40 coordinated genes ([@b26-bmj-44-4-1007]), which turns out to create difficulty to obtaining the complete pathways by cloning of small inserts.

Currently, there are some kits (*e.g.*, kit Ultra Clean Mega Soil DNA from Mo Bio) and even diversified non-commercial extraction methods ([@b60-bmj-44-4-1007]) that, in part, allow for the circumvention of these difficulties; however, the physical-chemical nature of the environment directly influences their performance, requiring adjustments for each condition studied ([@b64-bmj-44-4-1007]; [@b85-bmj-44-4-1007]).

The use of metagenomics as a search strategy for the discovery of genes of interest significantly increases the potential success of these approaches because it covers a diversity that is not constrained by laboratory culturing. Because the wide diversity of the soil microbiota consists of a large genetic and biological pool that can be mined for the discovery of novel genes, entire metabolic pathways and their products ([@b16-bmj-44-4-1007]; [@b4-bmj-44-4-1007]), metagenomics offers a way to access an environment's microbial diversity in its entirety ([Figure 8](#f8-bmj-44-4-1007){ref-type="fig"}).

Use of Bioinformatics to Predict Protein Function
=================================================

How an important partner of metagenomic, the Bioinformatic analyses give support to identification of new genes for several medical and industrial important pathways. Since the second half of the 90s and the advent of automated DNA sequencers, there has been an explosion in the number of nucleotide sequences that are stored and analyzed, requiring a constant improvement in the computational resources. This demand has created an interface between computer science, molecular biology and the areas of statistics, mathematics and software engineering, giving rise to a new scientific field: Bioinformatics ([@b77-bmj-44-4-1007]).

Currently, bioinformatics is an indispensable tool for processing the large volume of data generated by increasingly sophisticated and elegant methodological approaches for assessing diversity, transforming them into data that are comprehensible to the scientific community.

Blast (Basic Local Alignment Search Tool), one of the most widespread bioinformatic tools for sequence analysis is a search engine based on the biological homology of DNA and amino acid sequences. Blast is a variation of the Smith and Waterman Algorithm ([@b91-bmj-44-4-1007]). The Blast algorithm allows for sequence comparison in five different ways: Blastp, Blastn, Blastx, tBlastn, and tBlastx according to the user's needs and nature of the database to be queried ([@b20-bmj-44-4-1007]).

The Blastp software compares amino acid sequences (query) against a protein sequence database (subject). The Blastn software compares nucleotide sequence input against a database of nucleotide sequences. Blastx compares nucleotide sequences, which are translated to all possible reading frames, against a database of protein sequences. The tBlastn software compares an amino acid sequence input against a database of nucleotide sequences translated into all possible reading frames. The tBlastx software compares the six possible reading frames of a sequence against the six possible nucleotide sequence translations found in the National Center for Biotechnology Information (NCBI) database ([@b20-bmj-44-4-1007]).

A powerful ally in the characterization of enzymatic groups has been the use of phylogenomics, which represents a set of methodologies that explores the relationships among biological sequences (*i.e.*, DNA and proteins), thus allowing protein function prediction based on known orthologs/paralogs genes ([@b90-bmj-44-4-1007]).

The use of global and local alignment, the construction of phylogenetic trees, and different database searches for homologous genes, motifs and conserved enzymatic domains using bioinformatic tools are part of the phylogenomic approach. The data obtained are then cross-referenced with biological information in the literature, and this is aided by the use of biostatistics indexes.

Use of Molecular Biology for the Production of New Polyketides
==============================================================

One of the most promising approaches for the discovery of novel bioactive compounds is related to the use of metagenomics to search for new biosynthetic genes for cloning and expression in a heterologous or homologous host that does not contain the specific pathway ([@b46-bmj-44-4-1007]).

Consequently, for the expression of the genetic material of a new enzyme or enzymatic group recovered by metagenomics, it is necessary to introduce this material into a living organism capable of executing the new genetic information, resulting in the translation of the enzyme (or group of enzymes) into its active conformation. This means that the success of research aimed at producing new molecules by this strategy is restricted by the availability of a heterologous/homologous host compatible with the correct expression of the exogenous gene or even a native host with modified pathways to not interfere with detection of the new product. In the case of PKS II-related genes from *Streptomyces*, there are available native heterologous hosts (*i.e.*, *Streptomyces lividans*, *S. albus,* and *S. coelicolor*) and non-native heterologous hosts developed from mutant strains of *Escherichia coli* that have been specifically created to expression genes from this group ([@b63-bmj-44-4-1007]; [@b103-bmj-44-4-1007]; [@b4-bmj-44-4-1007]).

The availability of these strains is a key point in the search for new drugs because the particularities of *Streptomyces* gene sequences significantly reduce compatibility with other possible hosts that are commonly employed for the heterologous expression of other groups. One of the most limiting factors for the expression of exogenous proteins in the group in question is related to their own set of preferred codons (codon usage), which is present in most of the *Streptomyces* genome. Codon usage can act as a limiting factor for the exchange between the native host's gene of interest and the heterologous host that will be used for expression because if a codon set predominates in a genome, it is natural that the majority of tRNAs (RNA transporters) available in the organism will correspond to this preferred codon. Thus, the translation of an exogenous protein with low frequency preferred codons in a candidate host will not occur correctly, or the protein will be expressed at low levels due to the lack of cistrons (tRNAs) corresponding to the rare triplets.

Using a two-dimensional distribution map of preferred codon usage in the most studied living organisms, [@b36-bmj-44-4-1007] established considerations on groups of organisms that share preferred codons because these groups can be deduced based on their spatial proximity in a multivariate statistical chart ([Figure 9](#f9-bmj-44-4-1007){ref-type="fig"}).

Thus, based on the graph, it can be inferred that *Saccharomyces cerevisiae* would be the most suitable candidate for the expression of genes from the *Arabidopsis* plant and genes from the *Caenorhabditis elegans* nematode worm. At the same time, there is a closer relationship between the bacterial generas *Escherichia coli and Bacillus.* However, all seven organisms cited share more codon usage with each other than with *Streptomyces* (they are distant from all others in the map's spatial conformation).

The codon usage pattern of *Streptomyces* has been defined by the authors as the most extreme studied because it is known that for the *Streptomyces coelicolor* species, the majority of codons have a C or G as a terminal nucleotide, reflecting the high G/C nitrogenous bases content (approximately 71%) in the species analyzed. The codon usage profile for this genus explains the difficulty in expressing genes derived from *Streptomyces* using organisms from another genus as hosts ([@b36-bmj-44-4-1007]).

However, if other organisms are used for expression, the efficiency conditions for translation of the protein of interest can be improved by molecular engineering. In the specific case of the expression of enzymes involved in type II polyketide biosynthesis, the literature reports the use of *Escherichia coli* by two different approaches.

One approach consists of the modification of the codons present in the gene sequence for the set of triplets optimized as the most abundant in *E. coli* and thus for which the heterologous host machinery is fully functional ([@b4-bmj-44-4-1007]). Another approach consists of changes throughout the heterologous host genome (*Escherichia coli*) that increase the occurrence of rare codons, which limit the expression of genes derived from *Streptomyces.* The advantage of such mutant *E. coli* strains is the versatile use of the same organism for the expression of different polyketide genes coupled with the rapid growth of *E. coli* compared to *Streptomyces.* However, even if these mutants prove suitable for the enzymatic expression and production of simple polyketide structures, the expression level of these metabolites is greater in the heterologous hosts of the *Streptomyces* group ([@b4-bmj-44-4-1007]; [@b73-bmj-44-4-1007]).

Methods of Molecular Engineering for Expression of Large Gene Clusters
======================================================================

A promising method for the generation of novel bioactive compounds explores the use of the combinatorial biosynthesis of enzymes from different PKS pathways even from pigments and searching for the rational design of new drugs by homologous/heterologous biosynthesis ([@b87-bmj-44-4-1007]; [@b81-bmj-44-4-1007]). For homologous expression involving the substitution of native pathways for others engineered with the addition or silencing *(knockout)* of a given gene or the exchange of well conserved regions between close organisms, an interesting alternative is the use of cross recombination (*i.e.*, crossing-over). This recombination occurs due to common regions between the host chromosome and the recombinant element, which allows for the recognition and exchange of fragments by crossing-over events such that the insertion of exogenous material takes place at specific sites and is not limited by the DNA fragment size. However, there is not always a similar region in the host organism to guide gene insertion. In many situations, a desirable feature of a good host is to lack (naturally or artificially) certain pathways, facilitating the detection of successful mutants through phenotypic change. In such cases, even when dealing with the exchange between homologues, it is often necessary to add a region of homology so that the fragment may be integrated into the genome at the desired position ([@b29-bmj-44-4-1007]; [@b92-bmj-44-4-1007]).

For a long time, one of the biggest challenges for the heterologous expression of PKS gene clusters was the manipulation and efficient cloning of large DNA fragments. While using the classical methods of engineering (*i.e.*, PCR amplification, restriction digestion, and ligation experiments), it is possible to manipulate sequences measuring 15--20 Kb in length. This practice is inefficient and tediously time-consuming when cloning larger fragments. Therefore, the method is no longer recommended because more effective approaches for large inserts have been reported ([@b80-bmj-44-4-1007]; [@b29-bmj-44-4-1007]; [@b95-bmj-44-4-1007]).

In this context, systems based on mechanisms such as RED/ET λ phage recombination joined with large molecular engineering constructs have been elegantly designed to facilitate the transposition of large inserts. The RED/ET regions and transposons are integrative DNA elements called episomes, which are, by definition, autonomous replication elements that, unlike common vectors such as most plasmids and cosmids, have the ability to integrate into the host genome. These systems can be adapted using commercially available kits (*e.g.*, Red/ET Recombination System - Genebridges, Germany) that include vectors containing genes for special enzyme expression (or the purified enzyme) and specific inverted sequences (ITs). Construct adaptation involves the addition of homology arms (HAs) measuring approximately 40--50 bp for each recombination step between the large fragments and often involves the use of selective markers that are not inherited in the final inserted fragment ([@b83-bmj-44-4-1007]; [@b80-bmj-44-4-1007]).

Another promising possibility is the use of transposons (*e.g.*, the *MycoMar transposon* from *Drosophila mauritiana),* which may be combined with RED/ET recombination sites and have as an advantage the transposition of entire pathways in homologous and heterologous hosts, with 60 kb inserts already reported as generating stable mutants with high recombination rates ([@b29-bmj-44-4-1007]). An advantage of this method compared to that previously mentioned is the possibility of inserting a fragment without the need to include a homologous sequence.

Metagenomic Studies Conducted at the LBMP
=========================================

In one of the first metagenomic studies performed at the Microorganisms and Plants Biochemistry Laboratory ("Laboratório de Bioquímica de Micro-organismos e Plantas; LBMP") at the Technology Department of São Paulo State University ("Universidade Estadual Paulista - UNESP") Jaboticabal Campus, [@b89-bmj-44-4-1007] compared environmental DNA samples obtained from two areas (*i.e.*, under an eucalyptus arboretum and under native forest) to verify the biodiversity of microbial communities by 16S rDNA sequencing. The results showed that 72% of the analyzed sequences were novel and came from bacteria that had not been sequenced yet, suggesting an important source of genetic sequences potentially useful as biotechnological tools. The microbiota composition differed between the two environments. Under the native forest, microorganisms belonging to the phylum *Bacteroidetes* and *Planctomycetes* appeared in greater quantity, while under the eucalyptus arboretum, the predominant sequences were classified as *Actinobacteria*, *Firmicutes,* and *Verrucomicrobia.* An interesting observation was that the population of actinobacteria was greater in the area under the eucalyptus arboretum. These microorganisms are of great importance in biotechnology as producers of bioactive molecules, and this finding indicates that this soil can be a promising source for the mining of new genes related to antibiotic production ([@b89-bmj-44-4-1007]).

That study led to the construction of a metagenomic library from the soil studied with high molecular weight inserts to search for genes involved in polyketide biosynthesis. The library contains 9,320 clones and was constructed in cosmid vectors with cloned inserts measuring approximately 20 to 45 kb. From this library, assessments were made to detect the presence of genes involved in the antibiotic biosynthesis from PKS I ([@b85-bmj-44-4-1007]) and PKS II ([@b32-bmj-44-4-1007]).

Besides the metagenomic library constructed from soil under eucalyptus litter, the LBMP team also constructed libraries from mangrove soil, sugarcane straw soil, and from a petroleum-degrading consortium, while others are still under construction. These collections have been mined to search for several genes of industrial interest including catalases, amylases, lipases, peptidases, cellulases, antibiotics pathway genes, xylose-isomerases, and phosphatases among others using different mining approaches, such as the use of hybridization probes, degenerate primers, and biochemical assays.

Likewise, other diversity libraries were constructed (*i.e.*, 16S rDNA and ITS) including those obtained from activated sludge ([@b99-bmj-44-4-1007]), native forest soil and commercial monocultures ([@b75-bmj-44-4-1007]) and other sources. The accessed diversity will be employed for the construction of an EcoChip, which may eventually be used to rapidly identify organisms present in different habitats, thus enabling comparative studies between communities under the variables of time and space. As previously mentioned, metagenomic DNA is a promising source of new genes that encode molecules with potential biotechnology application, and the search for new antibiotic pathways is an important line of research developed in our laboratory. By way of illustration, the following items describe the methodological strategies and the main results obtained by our team in the search for new polyketide pathways.

Metagenomic Library Construction and the Search for Genes Involved in Type I PKS Polyketide Biosynthesis
========================================================================================================

The type I PKS, which is also known as modular, constitutes one of the main pathways studied in the search for new bioactive compounds. In a study involving the search for new type I polyketide antibiotics ([@b85-bmj-44-4-1007]), the goal was to recover and study PKS gene sequences from metagenomic DNA. For this purpose, a cosmid metagenomic library was built to search for type I PKS genes. A cosmid was subcloned and fully sequenced yielding a 29.6 kb contig. Analysis of the sequence contained in the insert revealed the presence of 21 open reading frames (ORFs), and one of which corresponded to a typical PKS module measuring 6,498 bp. Computational and phylogenetic analyzes were conducted to better understand the PKS gene found and the other ORFs present in the metagenomic DNA insert.

For metagenomic library construction, soil samples were collected under an eucalyptus arboretum that is planted on the UNESP campus in the city of Jaboticabal, State of Sao Paulo, Brazil in February 1969. This soil was characterized by molecular phylogeny in a previous study ([@b89-bmj-44-4-1007]). Twenty single samples were collect at random in a zigzag pattern at a depth of 0--20 cm, covering the entire area. The samples were pooled and homogenized, resulting in a composite sample. The samples were immediately transported to the laboratory for DNA extraction. Metagenomic DNA was extracted from 1 g of soil using the FastDNA^®^ Spin kit for soil (MP Biomedicals, Irvine, CA, USA). A cosmid library was constructed using the pWEB-TNC^™^ Cosmid Cloning Kit (Epicentre Biotechnologies Madison, WI, USA). Metagenomic DNA analysis showed that the sample had sufficient quality and integrity for cloning. A library of 9,320 clones was constructed in cosmid vectors from 10 μg of metagenomic DNA.

The library was mined for the presence of biosynthesis genes for modular polyketides biosyntheses (PKSI). The mining for PKS genes was performed by PCR using cosmid DNA obtained from pools of 96 clones using the alkaline lysis method as the template ([@b83-bmj-44-4-1007]). As previously described ([@b15-bmj-44-4-1007]), two sets of degenerate primers that were complementary to highly conserved regions in type I PKS genes were used. The PCR-positive pools were subjected to individual cosmid DNA extraction and PCR amplification to identify positive single clones. In total, 15 PCR-positive pools were amplified, and from these, three individual clones were identified. The three amplicons were sequenced, and the sequences were compared to available database sequences using the Blastn tool. One of the amplicons showed homology with PKS sequences and was selected for subcloning and sequencing. The mining of the metagenomic library by PCR has proven to be an efficient method, allowing for the identification of a clone whose insert contains genes possibly involved in polyketide biosynthesis.

Clone B7P37, whose amplicon showed homology with PKS sequences, had its cosmid subcloned and fully sequenced. Sequencing of the selected cosmid was performed using the shotgun sequencing technique as previously described ([@b88-bmj-44-4-1007]). Briefly, fragments measuring approximately 1.5 to 2 kb in length were separately cloned into pUC19DNA/SmaI (Fermentas) vectors. The plasmid DNA was obtained by the alkaline lysis method ([@b83-bmj-44-4-1007]), and the clones of the sub-library were subjected to automated DNA sequencing. The raw electropherogram data were analyzed by PhredPhrap ([@b21-bmj-44-4-1007]; [@b22-bmj-44-4-1007]) and Consed ([@b35-bmj-44-4-1007]) to generate sequences in FASTA format to evaluate quality and alignment. Phred values above 40 were considered high quality. The ORFs were determined using the ORF Finder software (NCBI). Gene annotation was performed from the ORFs amino acid sequences by searching for similarities to proteins present in different databases using the Blastp local alignment tool. A search for functional domains was also performed using the protein signatures database InterPro ([@b78-bmj-44-4-1007]). For PKS catalytic domain annotation, the PKS/NRPS annotation tool was used ([@b2-bmj-44-4-1007]). Global nucleotide and amino acid sequence alignments were performed using the software Clustal X ([@b58-bmj-44-4-1007]).

The metagenomic DNA insert obtained was 29,697 bp long. The mean GC content was 64%. Twenty-one ORFs were identified ([Figure 10](#f10-bmj-44-4-1007){ref-type="fig"}). The potential roles of the genes contained in the ORFs were determined by comparison with similar sequences present in the databases and functional domain analysis ([Tables 1](#t1-bmj-44-4-1007){ref-type="table"} and [2](#t2-bmj-44-4-1007){ref-type="table"}). All possible genes found in the sequenced region displayed typical characteristics of bacteria, and when subjected to database homology searches, each of the translated ORFs showed greater similarity to bacterial proteins.

ORF 1 measured 6,948 bp, corresponded to a PKS module, and presented homology with myxobacteria type I PKS (36% identity and a 50% Blastp similarity with *Chondromyces crocatus* CndA protein, its closest neighbor). The determination of catalytic domains present in the module was performed using the PKS/NRPS annotation tool ([@b2-bmj-44-4-1007]), and the enzymatic domains module organization was determined as follows: KS-AT-DH-ER-KR-ACP ([Table 1](#t1-bmj-44-4-1007){ref-type="table"}).

The sequenced gene cluster contains other genes that may be involved in the biosynthesis of a possible polyketide. ORFs 2, 3, 4, 17 and 18 correspond to membrane transporters associated with the ABC transporter superfamily. These transporters perform active transport through the membranes of different types of molecules such as sugars, amino acids, oligopeptides, ions, and drugs. Numerous polyketide-producing microorganisms have at least one ABC transporter gene within the antibiotic biosynthesis gene cluster, which often confers drug resistance ([@b66-bmj-44-4-1007]).

The ORF 5 sequence showed homology to members of the reductases/short-chain dehydrogenase family that use NAD or NAD(P) as a cofactor. The ORF 6 sequence showed homology to members of the NAD-dependent epimerases/dehydratases family. ORF 7 appeared to be a member of the aspartyl/asparaginyl beta-hydroxylase family of proteins that catalyze oxidative reactions in a variety of metabolic processes. ORFs 8 and 9 showed homology with the fatty acid desaturase family that catalyzes the insertion of a double bond in the delta position of fatty acids. ORF 10 belongs to the carbohydrate kinase family. ORF 11 belongs to a family that includes several FAD-dependent oxidoreductases. ORF 12 belongs to the periplasmic binding protein-like II family. ORF 13 showed homology with the Tat (twin-arginine translocation) pathway signal sequence protein family. ORFs 14, 15 and 16 were classified as putative proteins with unknown functions. ORF 19 belongs to the monooxygenases family, which incorporates a hydroxyl group on substrates is found in several metabolic pathways. ORF 20 was classified as belonging to the aldo-keto reductase family, and ORF 21 was classified as belonging to the quinoprotein amine dehydrogenase family.

ORF1 Domain Analysis
====================

Phylogenetic analyzes were conducted to locate the KS and AT domains of the metagenomic clone within a phylogenetic tree constructed with domains from 19 PKS gene clusters that are already characterized and available in the PKSDB database ([@b105-bmj-44-4-1007]). These 19 PKS gene clusters contained 182 KS domains and 188 AT domains. Through phylogenetic analysis of the KS domain, it was observed that the metagenomic domain sequence was grouped outside the large monophyletic group that includes the actinomycetales, suggesting that the clone does not belong to this order ([Figure 11](#f11-bmj-44-4-1007){ref-type="fig"}). However, this hypothesis cannot be completely supported considering that functional limitations may have led some genes to evolve differently from other genes that encode typical KS domains ([@b30-bmj-44-4-1007]). For example, KS domains that catalyze the entry of an amino acid chain (hybrid group) and extender modules (KS^Q^) are grouped separately. In the obtained phylogenetic tree, the metagenomic KS domain appears as a sibling group of domains that correspond to extender modules. The SEARCHPKS tool ([@b105-bmj-44-4-1007]) also classified the metagenomic KS as an extender module.

The sequence of the metagenomic KS active site was analyzed in relation to the functionality of the domain, and the presence of cysteine in the active site and the conserved sequence DTACSSSLVA, which is present in the KS functional domain, was observed ([Figure 12](#f12-bmj-44-4-1007){ref-type="fig"}). In KS extender modules, there is a substitution of a cysteine in the active site for a glutamine (KS^Q^) in *Streptomyces* systems and a serine (KS^S^) or tyrosine (KS^Y^) in myxobacteria systems ([@b68-bmj-44-4-1007]; [@b49-bmj-44-4-1007]). Therefore, it can be stated that the metagenomic KS is functional; however, it is not possible to predict whether it corresponds to an extender module.

Substrate recognition, which is defined by the AT domain of the PKS module, is the most important factor that determines the structure and diversity of a polyketide ([@b30-bmj-44-4-1007]). In the AT domains phylogenetic tree, specific domains for malonyl-CoA and methylmalonyl-CoA were grouped into two distinct clusters ([Figure 13](#f13-bmj-44-4-1007){ref-type="fig"}). The metagenomic AT domain was grouped outside of any malonyl-CoA or methylmalonyl-CoA clusters. For this reason, it was not possible to make any prediction of substrate incorporation based on the phylogenetic analysis.

Among the first 25 results obtained for substrate prediction using the SEARCHPKS tool ([@b105-bmj-44-4-1007]), 19 coincided with methylmalonyl-CoA, which was ranked in the first position, 2 coincided with ethylmalonyl-CoA, 2 coincided with malonyl-CoA, 2 coincided with glyceryl 2-CoA and 1 coincided with methylmalonyl-CoA/propionyl-CoA. Moreover, the YADAV prediction for the metagenomic AT domain provided similar values for the different substrates (between 6×10^−54^ and 3×10^−46^).

PKS modules may contain one or more inactive domains. These inactive domains can be generally identified by analysis of conserved regions corresponding to the active site. The consensus region of the active site of a KR is GxGxxGxxxA ([@b2-bmj-44-4-1007]). The corresponding region of the metagenomic KR domain is GxSxxGxxxA, indicating that this KR is most likely non-functional ([Figure 12](#f12-bmj-44-4-1007){ref-type="fig"}). An inactive KR domain leads to superfluous DH and KR domains.

In many cases, the colinearity between the genetic organization and sequence of enzymatic transformations involving type I PKSs is so strong that various structural features of a product can be predicted with confidence from gene sequence analysis. In the case of metagenomic PKS, prediction was not possible, and this can be explained by the fact that the metagenomic approach allows for the study of gene sequences with completely unknown functions. To definitively prove the involvement of the discovered genes in polyketide biosynthesis, studies on the expression and inactivation of these genes are needed. This work demonstrates that metagenomic DNA represents a promising source of new genes that can be used in combinatorial biosynthesis experiments aimed at the identification of new molecules.

Mining for PKS II using metagenomic libraries
---------------------------------------------

Another study conducted by the LBMP for the mining and characterization of new PKS pathways involved the search for conserved KS sequences of aromatic polyketides by PCR amplification as a detection strategy for metagenomic clone candidates of host polyketides pathways; this was followed by sequencing and bioinformatic analysis of the inserts found in PCR-positive clones ([@b32-bmj-44-4-1007], [@b33-bmj-44-4-1007]).

The search for new PKS pathways exploits the highly diffusible characteristic of these metabolites among the most diversified groups of microorganisms, persisting (thanks to molecular engineering intervention) after more than half a century of "harassment" from intense scientific research as the most promising source of new pharmacological chemical structures. A decisive factor for the spread of polyketide pathways is the fact that these small molecules will often confer adaptive advantages to their host and can be propagated by plasmids. The mechanism that maintains polyketide evolution is based on the high maintenance cost of these pathways in the organisms that possess them. The moment that these molecules do not confer adaptive advantage, their evolutionary lifetime will be shortened ([@b26-bmj-44-4-1007]). This negative selection (*i.e.*, increased metabolic expenditure) is coupled with the positive selection conferred by successful pathways, and creates an effective screening process for innovative bioactive molecules, greatly expanding the range of possibilities for the PKS research field.

In addition to this strong natural selection, the use of combinatorial biosynthesis can increase the ability to produce new polyketides by many orders of magnitude. This approach takes advantage of the fact that although each biochemical pathway typically results in a specific type of molecules, there will be enzymes common to all pathways within the same PKS family that are derived from homologous genes and conserved regions, even though they not are identical to each other.

This conservation of properties among homologous enzymes allows for a certain compatibility among enzymatic groups from different clusters. As with aromatic polyketide antibiotics, in which production of the final molecule is the result of the interaction of various enzymes belonging to a cluster, combinatorial biosynthesis allows for the assembly of molecules through enzymatic recombination between known producing organisms and novel genes obtained through metagenomic mining, which may be understood as a strategy of accelerating the evolutionary processes, resulting in new bioactive molecules.

To understand how promising this approach is, one must consider the immense number of complex peptides, polyketides, and other known chemical scaffolds that are widely diversified by the presence and arrangement of structures by processes including glycosylation, methylation, halogenation, acyl group attachment, and hydroxylation, which have evolved over billions of years in actinobacteria and fungi ([@b4-bmj-44-4-1007]).

The study of the most PKS II conserved unit, the "minimal pks", has been seen as a promising for the production of new molecules by enzymatic combination ([@b87-bmj-44-4-1007]). The peculiarities of the enzymes from different clusters from the specific selection of precursor units to compatibility with other enzymes involved in processes, including cyclases, ketoreductases, and aromatases, is decisive for the rational development of new molecules.

Shen and colleagues ([@b87-bmj-44-4-1007]) described an interesting study in which recombinant organisms were produced from the introduction of a *minimal pks* derived from spore pigment PKS II. This resulted in a variety of new carbon skeletons that were superior to those found in experiments that used a *minimal pks* from a natural antibiotics producer. With regard to the production of antibiotics by molecular engineering and the discovery of new PKS II pathways through metagenomics, the challenge is to identify the most promising pathway to obtain an interesting compound and making the right choice of which enzymes will be recombined, predicting their capacity for joint activity.

In this context, the methodology used in this study explored the homology concept to infer the catalytic functions of the putative enzymes through *in silico* analysis. Together, the strategies used allowed the recovery of an unknown pathway, which is described in detail through the identification of conserved enzymatic domains and the cross-referencing of information with previously published data. [Figure 14](#f14-bmj-44-4-1007){ref-type="fig"} is a comparison between the biosynthetic grouping obtained by metagenomics and some PKS IIs involved in pigments or antibiotics synthesis. There is a greater similarity within each compared cluster in the composition and arrangement of these genes and, on a smaller scale, between the genes of the two groups.

This characteristic is quite common for PKSs with a certain degree of compatibility between enzymes from different pathways, making them excellent raw material for molecular engineering and combinatorial biosynthesis ([@b39-bmj-44-4-1007]).

As observed, the grouping has an enzymatic arrangement that is similar to the physical arrangement of clusters related to spore pigments. However, there is a greater complexity of this gene cluster, particularly for ORFs that are related to modification enzymes that act after synthesis and modeling; this seems to be more representative of enzymes involved in antibiotic synthesis. However, similar to the data obtained for the KSα phylogeny, the comparative results do not allow for the discrimination of the cluster as antibiotic or pigment. Moreover, the presence of homology to carbohydrate degradation genes may indicate a cluster involved in lignin, cellulose, and chitin degradation. There have been reports of PKS II-derived clusters that have undergone differentiation and became active in this process ([@b43-bmj-44-4-1007]).

[Figure 15](#f15-bmj-44-4-1007){ref-type="fig"} shows a map of the putative genes found (*i.e.*, ORFs 1--22/Blastp homology) that were confirmed by the presence of related enzymatic domains (domains A-U/PRODOM database).

Phenetic Analysis of Alpha-Ketoacyl Synthases (KSAs)
====================================================

The KSA enzymatic subunit is related to the choice of elongation precursor for the biosynthesis of PKS II antibiotics such that differences in its sequence may reflect subclasses of different molecules ([@b67-bmj-44-4-1007]). Therefore, a phenetic analysis was performed between the likely metagenomic KSA (ORF 15) and other sequences available in the database; among these, the KSAs of PKS II pigments and antibiotics were selected. The use of phenetics allows for the detection of similarities among the metagenomic KSAs and other diversified pathways by comparing conserved KSA gene regions ([Figure 16](#f16-bmj-44-4-1007){ref-type="fig"}).

It may be noted that there was a split of the sequences into two main groups except for that of the KSA from the fatty acid synthase (FAS) used in the outgroup and the KSA from *Streptomyces resistomycificus*. The first group ([Figure 16A](#f16-bmj-44-4-1007){ref-type="fig"}) contained KSAs from known aromatic polyketide antibiotic producers. The second group was divided into two branches: one containing KSAs related to spore pigment production ([Figure 16C](#f16-bmj-44-4-1007){ref-type="fig"}), and the other comprised three sequences ([Figure 16B](#f16-bmj-44-4-1007){ref-type="fig"}): the metagenomic KSA (metagenomic putative KS-alpha) and KSAs belonging to two strains of *Streptomyces* including *S. hygroscopicus* ATCC 53653 (ZP_05513869.1) and *S. bingchenggensis BCW-1* (ADI05885.1), whose action forms were still not described. These analyzes suggest the possibility that the metagenomic cluster is involved in the synthesis of a new metabolite that is different from the known classes with a pathway involved in the synthesis of a new pigment. This result shows how metagenomics provides access to unknown gene diversity, providing a wide range of possible sources of enzymes for combinatorial biosynthesis of new pharmacological molecules.

Prediction of Protein Structure
===============================

There are few data concerning the three-dimensional structure and organization of PKS II enzymatic complexes, which undoubtedly limits aromatic polyketide rational design strategies. However, 3-D structural data of some enzymes involved in the pathway provide the use of strategies that aim to clarify how interprotein interactions occur ([@b11-bmj-44-4-1007]). An important milestone in the early studies of pathway protein interactions was reached by the X-ray crystallization of KS protein and its heterodimeric form (KSA/CLF) from *Streptomyces coelicolor* ([@b50-bmj-44-4-1007]), allowing spatial knowledge of the cavity formed by the subunits responsible for the catalysis of the decarboxylative condensation reactions that characterize the polyketides bonds. Together, KSA, CLF, and ACP form an enzymatic complex called minimal pks, which dictate the nature and chain length of the substrate. The noncovalent attraction between these proteins is responsible for the acquisition of its functional form and the architecture of the active site. Besides these proteins, the enzymatic complex often depends on interaction with other enzymes to become active. The cyclases, for example, seem to decisively act on the stability of the enzymatic complex, preventing the elimination of short polyketide chains in the active site to ensure a better performance of the pathway ([@b11-bmj-44-4-1007]).

The use of structural modeling by homology allows for functional inferences that simulate the folding of proteins related to the genes found in addition to the visual comparison of metagenomic 3-D models obtained with 3-D structures that were previously determined by X-ray crystallography or nuclear magnetic resonance (NMR). For this reason, this strategy was used to characterize the ORFs studied.

For structural prediction, 3-D models were generated using the Swiss-model software (<http://swissmodel.expasy.org>, accessed in December 12 of 2010), and they were applied as model structures that were resolved by classical methods using model identity values higher than 30% (recommended for obtaining accurate models; [@b18-bmj-44-4-1007]). The models were checked for their predictive ability and correspondence with functional biological structures by evaluating spatial distribution parameters using the Prosa-web (<https://prosa.services.came.sbg.ac.at/prosa.php>, accessed in December 20 of 2010) Qmean, Verify3D and Procheck (<http://swissmodel.expasy.org/workspace/index.php?func=tools_structureassessment1>, accessed in December 20 of 2010) software packages.

A high-accuracy structural model (both in experimental and *in silico* modeling) should have approximately 90% of its amino acids located in the most favorable region of the Ramachandran plot (PROCHECK). However, it is assumed that at 85% and above, it is possible to obtain models with a good confidence index ([@b18-bmj-44-4-1007]). [Table 3](#t3-bmj-44-4-1007){ref-type="table"} lists the results obtained for the ORF model and the corresponding molds used by PHYRE. Only ORF 17 and its model did not achieve a value greater than 85%, and it showed the least identity in relation to the molds (30%).

ORF 15 showed the highest identity (57%), allowing for a high resolution structure as also observed by the Z-Score ([Figure 17](#f17-bmj-44-4-1007){ref-type="fig"}), which is a parameter obtained from the Prosa Web software that depicts how much a predictive structure has quality parameters comparable to those obtained for structures resolved by classical methods (*i.e.*, X-Ray Crystallography and Nuclear Magnetic Resonance), which returned an expected value for X-Ray Crystallography ([Figure 17B](#f17-bmj-44-4-1007){ref-type="fig"}, graph on the right: region in light blue). Although its Ramachandran index (PROCHECK) returned 0.6% amino acids in the non-allowed region, it can be observed in the updated Ramachandran plot (RAMPAGE; [@b61-bmj-44-4-1007]) that the two residues are glycine ([Figure 17B](#f17-bmj-44-4-1007){ref-type="fig"}, center); in a way, this region is not prohibitive because of its short side chain (only one H). This result also reflects the high conservation of these proteins.

The predicted model could also be used in enzyme-substrate docking studies that are suitable for substrate prediction, and this is highly desirable because KSAs are involved in the choice of the elongation substrate (*i.e.*, malonate, methyl-, and ethyl- malonate among other derived substrates) and this specificity sometimes allows for differentiating pathways of distinct antibiotic classes ([@b67-bmj-44-4-1007]). [Figure 18](#f18-bmj-44-4-1007){ref-type="fig"} shows the results of the Qmean scoring for ORF 15 and the model.

Analysis of the scores given by the Qmean software allows for the evaluation of how well a particular 3-D structural model assumes the configuration expected for a given combination of specific amino acid residues, taking into account the interactions between them and the different chemical environments. This analysis is employed to evaluate both 3-D models obtained by classical methods and *in silico*-predicted models. The Qmean color scale indicates how close a model is to the ideal with the regions shown in blue indicating high-quality prediction (deviations are lower than 1 Å), and the red regions indicate lower predictive power (deviations above 3.5 Å). ORF 15 exhibited a structural pattern with a quality that resembles that obtained for the model structure, with most of the residues occupying an ideal conformation. As observed in [Figure 18](#f18-bmj-44-4-1007){ref-type="fig"}, the graphs to the right of each model, the overall pattern of scores evaluated by Qmean, were within normal range for both structures.

[Figure 19](#f19-bmj-44-4-1007){ref-type="fig"} shows a comparative analysis obtained through the Procheck software for the secondary structure of ORF 15 and the mold 1TQYA.

As observed in [Figure 19](#f19-bmj-44-4-1007){ref-type="fig"}, ORF 15 differs from the model structure. ORF 15 is larger than the model and has two more beta sheet structures than the model (peptide region: 397--418). Moreover, ORF 15 differs in the length of the beta sheet structures in the peptide regions 260--270 and 304--307, where it is possible to observe larger beta sheets in the ORF 15 structure. These differences in the secondary structure will affect the overall protein structure, which can directly affect its functional characteristics by interfering with the redox potential and substrate affinity.

The KSA and CLF structures are subunits of the same enzyme. KS, which forms a KSA/CLF heterodimer in its quaternary structure, can appear as a single copy or, as found in the 1TQY model *(Streptomyces coelicolor),* as an octahedral structure that is formed by four identical monomers with each one constituted by a KSA/CLF dimer.

All of the structural prediction results obtained indicated good quality models that can be used in enzymatic contact analysis to predict the KS quaternary structure through protein-protein docking simulation for ORFs 15 and 16. Other CLFs obtained in the literature by experimental methods were also analyzed to verify the compatibility of the metagenomic KSA model. Analysis of protein-protein docking was performed using the GRAMM-X software ([@b98-bmj-44-4-1007]).

For this purpose, the three models with the highest identity obtained by ORF 16 submission (metagenomic CLF) in PHYRE were used: the 1TQYH model (47% identity), which is related to the KSA of the actinorhodin polyketide putative beta-ketoacyl; the 1j3nA model (34% identity), which is related to the *3-oxoacyl-(acyl-carrier protein) 2 synthase II* from *Thermus thermophilus hb8* crystal structure that is associated with FAS; and the 1e5 mA model, which is related to a single chain CLF from *Synechocystis sp.* ([@b69-bmj-44-4-1007]). [Figure 20](#f20-bmj-44-4-1007){ref-type="fig"} shows the obtained data.

From [Figure 20](#f20-bmj-44-4-1007){ref-type="fig"}, it is evident that the B and D simulations gave a prediction of contact between proteins that best reflected the situation found for the metagenomic model (A). The CLF used for model B (1tqyH) was found with its origin connected to KSA 1tqyA, forming a dimer that combines with another three identical dimers, making an octahedral structure. The CLF used in model D represents a KS subunit that binds to a KSA, also forming a dimer, though in a single copy. One of the differences between the two CLFs can be observed by the detail indicated with the arrows, showing the absence of antiparallel beta sheet structures in model D, which is indicated for the metagenomic CLF (A) and the CLF 1e5 mA (D).

Simulation C returned a model that was completely different from the metagenomic model arrangements. This situation was expected because the CLF 1J3nA actually belongs to FAS and not KSA, indicating homology by paralogs. This result allows for the visualization of a situation in which there would be no compatibility among the candidate enzymes to a combinatorial biosynthesis assay, representing a rapid diagnosis of the chances of succeeding in enzymatic recombination because there are expectations of using the KS FAS condensation enzyme for the production of new drugs, exploring the relationship between PKS and FAS pathways ([@b69-bmj-44-4-1007]).

Metagenomics is undoubtedly a powerful tool for the discovery of new enzymatic pathways, and this work has enabled the advancement of several more steps in the predictive analysis of protein function by homology, thus shedding light on the three-dimensional folding of these molecules. This study allowed for the fast characterization of metagenomic putative enzymes completely in silico, which confirmed the homology between the studied ORFs, detecting the diversity of the 2-D and 3-D structural patterns, and enabling the use of docking to restore KS enzymatic subunits to allow the simulation of KS quaternary structure in a first step towards the study of possible ligands and substrates. It was also possible to simulate recombinant situations among the metagenomic KSA subunits and CLFs in the literature, observing variations among the different recombinant situations.

The results obtained will support future studies of heterologous gene expression and will be useful for determining the most promising experimental design to obtain enzymatic expression products for characterization of pathway enzymology kinetics. The generated 3-D models will be used in enzymatic interaction predictive studies, particularly in protein-protein and protein-ligand docking strategies, to determine enzymatic substrates and to study the compatibility of catalytic subunits with enzymes from other pathways. Once the *in silico* strategies are validated through *in vitro* and *in vivo* experiments (heterologous host), the standardized methodology will be used to generate an internal LBMP database for metagenomic PKS enzymes to facilitate the recognition of promising enzymatic units for the rational design of new drugs. Other pathway enzymes have potential biotechnological application in other areas (*e.g.*, cellulases, laccases, peptidases, and oxidases) and will be studied in parallel employing the approaches described.

Conclusion
==========

Although no longer seen as an "innovation" as a biotechnological tool, the mature metagenomics has presented the fruits of hard work in the search of new gene clusters for the production of antibiotics and other metabolites of many industrial and environmental interests. At the vanguard of new technologies, such as research on "Single Cell" ([@b77-bmj-44-4-1007]; [@b76-bmj-44-4-1007]) and the genetic therapy, its potential is still at the threshold to be fully accessible, especially with regard to the largest extent created by new sequencing techniques, and how to support studies in transcriptome and metabolome.

Regardless, the problematic of the growing demand for new antibiotics face to which new drugs quickly become obsolete, is certainly a topic that can not be ignored, and as such will capture efforts worldwide in all its possibilities, making use of classical and modern pathways, while stimulates the emergence of new tools.

Also, if on the one hand, according Baltz: Molecular Engineering found the way to "Essentially attempts to speed up the process of evolution by many orders of magnitude to compete with natural evolution of new antibiotics" ([@b4-bmj-44-4-1007]) the evidence of counterpart dates at least 30,000 years ago ([@b17-bmj-44-4-1007]), considering the existence and evolution of multidrug resistance mechanisms *vs.* mere 80 years of use of antibiotics on human and animal therapy.

Thus, the dilemma of the roles of hero/villain for the antibiotics takes form while one should bear in mind that we are intensifying the selective pressure on this powerful way to use the plastic raw matter, found in nature, paradoxically acting as irrational use of antimicrobials protagonists'. More than new drugs, we strongly need a new attitude facing the public and environment health.
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![Representative polyketide structures including prominent bioactives. Reproduced from Methods in Enzymology, 2009, Vol. 459, cap. 1, Pages 3--16 with permission of Elsevier Ltd. ([@b104-bmj-44-4-1007]).](bjm-44-4-1009-f1){#f1-bmj-44-4-1007}

![Scheme of PKS catalytic reactions and dynamics. Reproduced from *Methods in Enzymology*, 2009, Vol. 459, cap. 1, Pages 3--16 with permission of Elsevier Ltd. ([@b104-bmj-44-4-1007]).](bjm-44-4-1009-f2){#f2-bmj-44-4-1007}

![Mechanisms of bacterial resistance to antibiotics (A) and Antibiotics resistance evolution showing the rapid development of resistance to multiple classes of antibiotics (B). Reproduced from Future Microbiology, January 2012, Vol. 7, No. 1, Pages 73--89 with permission of Future Medicine Ltd. ([@b84-bmj-44-4-1007]).](bjm-44-4-1009-f3){#f3-bmj-44-4-1007}

![New drug distribution by chemical family and research stage. A. Revenue in billions of dollars for the most commonly used antibiotics. B. Production pipeline of new drugs. Reproduced from *Nature Reviews Drug Discovery*, September 2010, Vol. 9, No. 9, Pages 675--676 with permission of Nature Publishing Group Ltd. ([@b37-bmj-44-4-1007]).](bjm-44-4-1009-f4){#f4-bmj-44-4-1007}

![Retention time averages of new molecules according to the pathological area, which were obtained from 2003 to 2007; \* The anti-infective category excludes AIDS antiviral agents (which are in their category). Reproduced from *Clinical Pharmacology & Therapeutics*, February 2010, Vol. 87, Pages 356--361 with permission of Nature Publishing Group Ltd. ([@b48-bmj-44-4-1007]).](bjm-44-4-1009-f5){#f5-bmj-44-4-1007}

![Public and private initiative contributions to the discovery of new drugs in different countries for the period between 1998 and 2007. Reproduced from *Nature Reviews Drug Discovery*, November 2010, Vol. 9, Pages 867--882 with permission of Nature Publishing Group Ltd. ([@b55-bmj-44-4-1007]).](bjm-44-4-1009-f6){#f6-bmj-44-4-1007}

![Evaluation of new drugs launched in Brazil from 1998 to 2001. Source: [@b102-bmj-44-4-1007]. Reproduced with permission of author.](bjm-44-4-1009-f7){#f7-bmj-44-4-1007}

![Some metagenomic contributions to the discovery of new drugs.](bjm-44-4-1009-f8){#f8-bmj-44-4-1007}

![Graphical spatial representation of codon usage of organisms often studied in the academic sector, correlating the degree of subject compatibility according to codon preference. Reproduced from *Trends in Biotechnology*, July 2004, Vol. 22, No.7, Pages 346--353 with permission of Elsevier Ltd. ([@b36-bmj-44-4-1007]).](bjm-44-4-1009-f9){#f9-bmj-44-4-1007}

![ORFs map of the sequenced metagenomic DNA insert for the clone B7B37. ORF1: PKSI biosynthesis gene cluster.](bjm-44-4-1009-f10){#f10-bmj-44-4-1007}

![Phylogenetic analysis of the KS domain. The reconstruction was computed for 182 protein sequences using the distance method (*i.e.*, NJ and JTT matrix) with 500 resamplings. The group named hybrid PKS/NRPS includes the KS domains that are preceded by NRPS (non-ribosomal protein synthesis). KS^Q^ and KS extender module domains with an ACP-KS-AT-AT-ACP organization were grouped and named the KS^Q^/2AT group. The KS domains that were tightly clustered were named after the produced polyketide. The ORF 1 sequence obtained from B7P37 clone from the metagenomic library is shown in bold.](bjm-44-4-1009-f11){#f11-bmj-44-4-1007}

![Alignment of the KS and KR domains of ORF 1 with different homologous KS and KR domains. Protein sequences were aligned using the ClustalX software. Only the region containing the active site of the enzyme is shown. The number corresponds software the amino acid position of the first residue listed in the first motif. The amino acids in bold are conserved residues or important motifs for the function of each domain. The active-site residues in the KS sequence are marked with an asterisk. The important motifs for the functioning of the KR residue are underlined.](bjm-44-4-1009-f12){#f12-bmj-44-4-1007}

![Phylogenetic analysis of the AT domain. The AT domains located outside the two major groups for malonyl-CoA and methylmalonyl-CoA remain unresolved by phylogenetic analysis. The sequence obtained from the metagenomic library is shown in bold.](bjm-44-4-1009-f13){#f13-bmj-44-4-1007}

![Comparative analysis of the B5-37 metagenomic contig and several PKS II clusters. A: PKSs pigments. 1: *act* spore pigment cluster (actinorhodin pigment) from *Streptomyces coelicolor*; 2: *whiE* spore pigment cluster from *S. coelicolor*; 3: *sch* spore pigment cluster from *S. halstedii*; 4: *cur* spore pigment cluster from *S. curacoi*; 5: *tcm* tetracenomycin pigment cluster from *S. glaucescens* ([@b106-bmj-44-4-1007]); 6: melanin cluster from *S. avermitilis* ([@b71-bmj-44-4-1007]) B: Gene grouping obtained for the metagenomic contig. 7: B5-37 metagenomic cluster (this work). C: Polyketides antibiotics gene grouping. 8: antibiotic cluster 1 from *S. avermitilis*; 9. antibiotic cluster 2 from *S. avermitilis* ([@b71-bmj-44-4-1007]); 10: actinorhodin antibiotic cluster ([@b3-bmj-44-4-1007]); 11: antrachinona antibiotic cluster from *Photorhabdus luminescens* ([@b8-bmj-44-4-1007]); 12: antibiotic A-74528 cluster ([@b108-bmj-44-4-1007]). Note: Images are not scaled to a size that is relative to the original clusters.](bjm-44-4-1009-f14){#f14-bmj-44-4-1007}

![Distribution of ORFs (1--22) and Domains (A--U) along the studied contig.](bjm-44-4-1009-f15){#f15-bmj-44-4-1007}

![Phenetic comparison of KSA genes for various PKS clusters available in the literature and the metagenomic ORF. A: PKS II antibiotics; B: PKS II undefined; C: PKS II spore pigments. The tree was generated using the Phylip bioinformatic tool package (Neighbor Joining, JTT matrix, Bootstrapping 1000) and was generated for a nucleotide sequence alignment translated into amino acids.](bjm-44-4-1009-f16){#f16-bmj-44-4-1007}

![Functional prediction for the model and ORF 15. Center: Ramachandran (Rampage) based on the torsion angles C-alpha and C-beta. Right: Z-score (Prosa Web).](bjm-44-4-1009-f17){#f17-bmj-44-4-1007}

![3-D structure quality evaluation through Qmean. A: Mold 1TQYA; B: ORF 15.](bjm-44-4-1009-f18){#f18-bmj-44-4-1007}

![2-D structure comparison between ORF 15 and the mold 1TQYA.](bjm-44-4-1009-f19){#f19-bmj-44-4-1007}

![Compatibility analysis between the metagenomic KSA against the metagenomic CLF (A), CLF 1tqyH (B), CLF 1j3nA (C), and CLF 1e5mA (D) that was obtained by protein-protein docking simulation (GRAMM-X). Continuous arrows: short and antiparallel beta sheets, dotted arrow: the absence of these structures.](bjm-44-4-1009-f20){#f20-bmj-44-4-1007}

###### 

ORF1 PKS biosynthesis gene cluster.

  Protein (gene)   length (pb)   Proposed function (protein domains with their positions in the sequence of aa)
  ---------------- ------------- -------------------------------------------------------------------------------------------
  PKS (pks)        6.498         KS (32-458), AT (558-852), DH (912-1069), ER (1399-1706), KR (1729-1908), ACP (2004-2070)

###### 

Probable role of the ORFs shown in [Figure 10](#f10-bmj-44-4-1007){ref-type="fig"}.

  Protein   length (aa)   Similar protein in the database            Bacteria of similar protein      Sim/Id(%)
  --------- ------------- ------------------------------------------ -------------------------------- -----------
  ORF1      2148          polyketide synthase                        *Chondromyces crocatus*          50/36
  ORF2      400           efflux RND transporter protein             *Xanthobacter autotrophicus*     66/48
  ORF3      357           efflux ABC transporter permease            *Brevundimonas* sp.              68/50
  ORF4      177           ABC transporter related                    *Xanthobacter autotrophicus*     76/58
  ORF5      231           oxidoreductase                             *Gemmata obscuriglobus*          51/35
  ORF6      330           NAD-dependent epimerase/dehydratase        *Reinekea* sp.                   61/44
  ORF7      233           peptide aspartate b-dioxygenase            *Legionella pneumophila*         59/40
  ORF8      369           alkane 1-monooxygenase                     *Acidiphilium cryptum*           53/37
  ORF9      336           delta 9 acyl-lipid fatty acid desaturase   *Rhodopirellula baltica*         65/49
  ORF10     494           glycerol kinase                            *Mesorhizobium loti*             79/68
  ORF11     507           FAD dependent oxidoreductase               *Methylobacterium* sp.           68/58
  ORF12     354           hypothetical protein                       *Marinobacter algicola*          58/37
  ORF13     327           hypothetical protein                       *Ruegeria pomeroyi*              62/43
  ORF14     135           hypothetical protein                       *Symbiobacterium thermophilum*   42/28
  ORF15     147           hypothetical protein                       *Chromohalobacter salexigens*    50/39
  ORF16     200           hypothetical protein                       *Sulfitobacter* sp.              64/44
  ORF17     242           ABC-type transporter                       *Polaromonas* sp.                52/33
  ORF18     326           ABC-type transporter                       *Methylobacterium nodulans*      57/42
  ORF19     378           monooxygenase                              *Agrobacterium radiobacter*      56/41
  ORF20     306           aldo/keto reductase                        *Thiomonas intermedia*           71/56
  ORF21     314           hypothetical protein                       *Nitrobacter hamburgensis*       69/49

(aa: amino acid, sim: similarity, id: Identities).

###### 

Mold/model stereochemical evaluation

  3D/L            Id.[a](#tfn2-bmj-44-4-1007){ref-type="table-fn"}   Percent of residues in Ramachandran Plot (Procheck)[b](#tfn3-bmj-44-4-1007){ref-type="table-fn"}   Score 3D Profile[\*](#tfn4-bmj-44-4-1007){ref-type="table-fn"}                                 
  --------------- -------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----- ----- -------- -------- ------
  *1TQYA* (394)   57                                                 87.5                                                                                               11.3                                                             0.6   0.6   155.98   180.22   0.86
  ORF15 (416)     57                                                 85.6                                                                                               13.6                                                             0.3   0.6   183.07   190.36   0.96
  *1TQYH* (402)   47                                                 87.2                                                                                               11.5                                                             0.9   0.3   192.39   183.90   1.04
  ORF16 (402)     47                                                 86.2                                                                                               12.2                                                             0.6   0.9   163.75   183.90   0.89
  *1NQ4A* (95)    33                                                 74.1                                                                                               21.0                                                             2.5   2.5   34.32    42.96    0.79
  *ORF17* (85)    33                                                 73.6                                                                                               18.1                                                             2.8   5.6   25.24    38.40    0.65

result in percentage for the most similar model (multiple alignments were used), Id.: Identity.

Ramachandran plot (PROCHECK) based on the torsion angles Φ and Ψ (C-alpha and N and C-alpha and C-peptide).

, Data calculated from the analysis using the software Verify3 (<http://nihserver.mbi.ucla.edu/Verify_3D/>). Total score: provided. Ideal score: Exp^−0.83\ +\ 1,008\ ×\ ln(L)^, and S~ideal~, which is equivalent to sequence compatibility with their 3-D structure and is obtained by dividing the total score and ideal score with ideal values above 0.45 S~ideal~. L.: number of amino acid residues ([@b18-bmj-44-4-1007]).
